Category Archives: Gene Therapy Clinics

Edited Transcript of BLFS earnings conference call or presentation 12-Nov-19 9:30pm GMT – Yahoo Finance

Bothell Nov 20, 2019 (Thomson StreetEvents) -- Edited Transcript of BioLife Solutions Inc earnings conference call or presentation Tuesday, November 12, 2019 at 9:30:00pm GMT

* Michael P. Rice

BioLife Solutions, Inc. - President, CEO & Director

BioLife Solutions, Inc. - CFO & Secretary

H.C. Wainwright & Co, LLC, Research Division - Research Analyst

Janney Montgomery Scott LLC, Research Division - MD, Head of Healthcare Research & Senior Equity Research Analyst

Good afternoon, ladies and gentlemen, and welcome to the Q3 2019 BioLife Solutions, Inc. Earnings Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Mr. Roderick de Greef, Chief Financial Officer. You may begin.

Roderick de Greef, BioLife Solutions, Inc. - CFO & Secretary [2]

Thank you, JP. Good afternoon, everyone, and thank you for joining us for the BioLife Solutions conference call to review the operating and financial results for the third quarter of 2019. Earlier this afternoon, we issued a press release which summarizes our financial results for the 3 and 9 months ended September 30, 2019. We also issued a press release this afternoon announcing our asset purchase of Custom Biogenic Systems or CBS.

As a reminder, during this call, we will make certain projections and other forward-looking statements regarding future events or the future financial performance of the company. These statements are subject to risks and uncertainties that may cause actual results to differ materially from expectations. For a detailed discussion of the risks and uncertainties that affect the company's business and that qualifies forward-looking statements, I refer you to our periodic and other public filings filed with the SEC. Company projections and forward-looking statements are based on factors that are subject to change, and therefore, these statements speak only as of the date they are given. The company assumes no obligation to update any projections or forward-looking statements except as required by law.

During this call, we will speak to non-GAAP or adjusted results and guidance. Reconciliations of GAAP to non-GAAP or adjusted financial metrics are included in the press release we issued this afternoon. These non-GAAP or adjusted financial metrics should not be viewed as an alternative to GAAP. However, in light of our M&A activity, we believe that the use of non-GAAP or adjusted metrics provides investors with a clearer view of our current financial results when compared to prior periods.

Now I'd like to turn the call over to Mike Rice, President and CEO of BioLife.

Michael P. Rice, BioLife Solutions, Inc. - President, CEO & Director [3]

Thank you, Rod, and good afternoon, everyone. Thank you for joining the call. I'm very pleased to discuss our Q3 results and activities. We have a lot to share, so I'll jump right in.

I'll start by sharing our vision of success for BioLife and our next major milestone we're focused on. First, some history. Over the last nearly 15 years, we built BioLife into a leading supplier of critical biopreservation media products used in cell and gene therapy manufacturing. We created the product categoryclinical-grade biopreservation media and worked very hard to convince developers in the cell and gene therapy space that traditional preservation cocktails and methods are not robust enough to best ensure commercial success. Our proprietary and optimized CryoStor and HypoThermosol media products have now been used in more than 400 customer clinical applications. Once we scaled our media business and reached profitability in 2018, we began to seek complementary growth opportunities. We, of course, considered a number of internal R&D projects, but on balance, a long time to market and then transposition we hold with CryoStor and HypoThermosol caused us to identify external opportunities to scale the business even faster and to take advantage of the current roll-up environment for bioproduction tools.

Earlier this year, we acquired Astero Bio and gained the ThawSTAR automated thaw product line. Later, we acquired the remainder of SAVSU Technologies that we didn't own and added the evo Cold Chain management system to our portfolio.

Our outlook for these initial acquisitions is very positive. And coupled with our just announced acquisition of Custom Biogenic Systems or CBS, we've defined our next major milestone for success as reaching $100 million in revenue. The vision of success we're focused on looks like this: BioLife will scale to become an even more deeply entrenched partner to cell and gene therapy companies by offering a diversified and differentiated portfolio of novel products and services that can improve quality by reducing risk in the manufacture, preservation, storage, delivery and thawing of these biologic therapies. I'll have more to say about CBS later in the call, so now I'll provide some comments about our existing business.

Turning to Q3 revenue. We experienced a soft quarter due to 2 customers ordering less media products than anticipated. Our media revenue and current total revenue is highly concentrated from less than 100 customers with about 50 generating the lion's share. This concentration is a primary driver for our M&A strategy to derisk our reliance on a concentrated customer base and a limited product portfolio.

In Q3, a large distributor had a significant sequential decrease in order volume due to it being the start of their fiscal year and a changeover to a new ERP system. On a positive note, we expect total 2019 calendar revenue from this distributor to nearly double from 2018. Also, one large therapy -- one large cell therapy contract manufacturer had a significant sequential decrease in order volume. We attribute this to the cyclical nature of contract work and the CMOs' dependence on end-user customer order patterns, which can be affected by the pace of enrollment in their clinical trials. Together, these 2 customers accounted for a nearly $1 million sequential revenue decrease from Q2. So far in Q4, order volume from these customers has returned to typical levels. But again, it's worth repeating that from time to time, we expect to experience sequential swings like this. And we're obviously working hard on the M&A front to expand our portfolio to not only derisk but also grow top line revenue.

Our other internal metrics for assessing how our regen med franchise is performing were on track in Q3. We gained 41 new direct cell and gene therapy customers, and we processed 18 new FDA master file cross-reference requests supporting customer use of CryoStor or HypoThermosol in pending human clinical trials of cell and gene therapies.

Integration of the Astero thaw products is on track. And to date, we've shipped over 200 ThawSTAR products, with most of these to the cell and gene therapy market segment. Progress continues on our new ThawSTAR CB automated thaw product for biologic materials frozen in bags. We plan to formally introduce ThawSTAR CB at the Phacilitate Cell and Gene Therapy Conference in Miami in January.

Updating you now on adoption of the evo Cold Chain management system. We continue to win new customers, including Adaptimmune, Autolus, Janssen, KBI Pharma, Mustang Bio, Nanjing Legend and Tessa Therapeutics. Product validations by several leading cell and gene therapy companies continue, and we look forward to sharing some new customer wins when appropriate. It's clear we've emerged as a new competitor in the cold chain management segment of cell and gene therapy manufacturing. As such, we're being put through a very robust qualification process by several multibillion-dollar worldwide biopharma companies, we believe, much more so than incumbent suppliers as our technology is truly innovative and is expanding the conversation to include quality aspects that prospective customers have not thought of before.

Our indirect network of distributors continued to perform well in Q3, generating 36% of total revenue, with 38% growth over Q3 last year. Key worldwide distributors for our media products include MilliporeSigma, STEMCELL Technologies, Thermo Fisher and VWR.

Turning now to our other significant news of the day. We announced the acquisition of nearly all of the assets of privately held Custom Biogenic Systems or CBS. CBS, based in a Northern Detroit suburb, is a leading designer, manufacturer and supplier of advanced liquid nitrogen freezers and related racks and accessories. We started a dialogue with CBS' CEO and founder in June of this year and immediately recognized several potential benefits of an acquisition, including adding a meaningful amount of revenue from the sale of complementary products, the ability to leverage our relationships in the cell and gene therapy space to accelerate adoption of CBS products and an opportunity to improve quality and reduce cost in our evo Cold Chain products by vertically integrating a U.S.-based supplier.

Recall that our vision is to supply products to our cell and gene therapy customers along as much of the longitudinal workflow as possible. With the acquisition of CBS assets, we now plug into the following workflows. Starting with the acquisition of source material, this includes preservation, cold chain transport, cryogenic storage and thawing before manufacturing. And now continuing with the manufactured biologic product, we play in the following work processes: preservation, cryogenic storage, cold chain shipment and on-site thawing before patient administration.

CBS is a great fit, and we look forward to integrating their operations into BioLife to realize the synergies we identified. CBS has several marquee customers in the cell and gene therapy space, and we see tremendous leverage to scale the business.

I'd like to make one last comment about our M&A strategy. While we've been very active this year and would not rule out some additional activity next year, our focus for 2020 will be on integrating the businesses we acquired.

Now I'll turn the call back over to Rod to present our financial highlights for Q3, some additional detail on CBS and our updated guidance for 2019 and preliminary revenue guidance for 2020. Rob?

--------------------------------------------------------------------------------

Roderick de Greef, BioLife Solutions, Inc. - CFO & Secretary [4]

--------------------------------------------------------------------------------

Thanks, Mike. Before reviewing our third quarter financial results, I'd like to make a few comments about our acquisition of CBS, which we announced earlier today. We purchased substantially all of the assets of CBS for $11 million in cash and issued 234,000 unregistered common shares having a value of $4 million. We have structured an earnout over 5 years whereby the owner of CBS could realize another $15 million in cash or stock if certain new product-related revenue levels are exceeded. We anticipate that CBS will have full year 2019 revenue of between $10 million to $11 million and a modest but positive adjusted EBITDA. We expect to realize $1 million to $2 million of incremental revenue contribution to our P&L for the balance of 2019.

Based on the introduction of a new line of liquid nitrogen freezers in 2020, we expect solid revenue growth over 2019. And although our gross margin will realize additional compression in the near term, based on the margin profile of capital equipment, we fully expect the acquisition will be accretive on an adjusted EPS basis and provide a positive adjusted EBITDA contribution in 2020.

Moving to our quarterly results. Total revenue for the third quarter of 2019 reached $6.6 million, representing a 25% increase over last year's third quarter revenue of $5.3 million. This quarter's revenue included $324,000 of sales related to the automated thaw products we acquired last April and $211,000 of evo-related revenue, which was acquired in early August. Biopreservation media revenue for the third quarter of 2019 was $6 million, up 15% compared to last year and lower than expected based on 2 customers ordering approximately $1 million less than expectations. As Mike mentioned, order volume from these 2 customers in Q4 is back in line with our internal expectations but unlikely to make up the order shortfall we realized in Q3.

Total revenue for the 9-month period in 2019 was $19.1 million, up 34% over revenue of $14.3 million in 2018. The adjusted gross margin for the third quarter of 2019 was 69.2% compared with 69.7% in the third quarter of last year. The slight decrease in gross margin reflects the lower margin profile of the automated thaw and evo product lines. Adjusted gross margin for the 9 months was 71% compared to 68.5% in 2018.

Adjusted operating expenses for Q3 totaled $4.5 million compared with $2.5 million in Q3 of 2018. The increase in adjusted operating expenses is primarily the result of the acquisitions of Astero and SAVSU and secondarily to increased head count necessary to support our overall growth and higher performance-based compensation. Adjusted operating expenses for the 9-month period in 2019 totaled $11.6 million compared with $7.2 million in 2018.

Adjusted operating profit for the third quarter of 2019 was $106,000 compared with $1.2 million in the third quarter of 2018. Adjusted operating profit for the 9-month period was $2 million compared to $2.6 million in 2018.

Adjusted net income attributable to common shareholders for the third quarter of 2019 was $215,000 or $0.01 per diluted share compared with $1.2 million or $0.05 per diluted share in 2018. For the 9-month period in 2019, adjusted net income attributable to common shareholders was $2.4 million or $0.10 per diluted share compared with $2.5 million or $0.12 per diluted share in 2018.

GAAP net income and EPS for the 3- and 9-month periods included a onetime gain on the acquisition of SAVSU of $10.1 million and $0.40 and $0.41 per share, respectively. Adjusted EBITDA for the third quarter totaled $925,000 compared to $1.7 million in the same period in 2018. And for the 9-month period, adjusted EBITDA was $4.3 million compared to $4 million in 2018.

With respect to our current outlook for 2019, we have updated the guidance we provided in August of this year, which includes the impact of acquiring Astero beginning on April 2, SAVSU from August 8 and now CBS from November 12. We expect total revenue for 2019 will be between $27.5 million to $31.5 million, reflecting year-over-year growth of 39% to 60%. This includes $1.2 million from the thaw product line, $500,000 from the evo technology and $1 million to $2 million from CBS.

Our adjusted gross margin for 2019 should be between 68% to 69%. Based on the acquisitions of SAVSU and CBS, we do expect the near-term compression of our gross margin of between 6 to 8 percentage points, ultimately climbing back into the mid-60s with increasing product revenue.

We expect 2019 adjusted operating expenses to be in the range of $16.5 million to $17.5 million. We expect that the additions of SAVSU and CBS will add between $1.2 million to $1.5 million in additional quarterly operating expenses above the $4.5 million we realized in Q3.

Finally, we expect to be positive on the operating, net income and EBITDA lines on an adjusted basis for the full year of 2019.

I would like to end my remarks with a summary of our share count. We currently have 20.7 million common shares issued and outstanding and a fully diluted share count of 27.2 million.

Now I'd like to turn the call back over to Mike.

--------------------------------------------------------------------------------

Michael P. Rice, BioLife Solutions, Inc. - President, CEO & Director [5]

--------------------------------------------------------------------------------

Thanks, again, Rob. In summary, I'm very bullish on the potential to grow BioLife to our next interim milestone of reaching $100 million in revenue. Our preliminary revenue guidance for next year has us more than halfway to this goal. The opportunity in the cell and gene therapy space is tremendous. We have a very solid reputation in the space as a trusted supplier. We worked very hard building customer relationships that have rewarded us with growth and the satisfaction of playing a part in helping our customers bring life-changing and life-saving biologic-based therapies to the clinic. I'd like to thank all of our shareholders for your support of BioLife.

Now we'll turn the call back over to the operator to take your questions. JP?

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) First question comes from the line of Jason McCarthy of Maxim Group.

--------------------------------------------------------------------------------

Unidentified Analyst, [2]

--------------------------------------------------------------------------------

It's Dave on the line for Jason. So I don't think I quite caught this here. Could you please repeat how many new customers did you guys get in the third quarter? Was it 41? I just wanted to make sure I heard that correctly.

--------------------------------------------------------------------------------

Michael P. Rice, BioLife Solutions, Inc. - President, CEO & Director [3]

--------------------------------------------------------------------------------

Yes. This is Mike. 62 total, 41 in the cell and gene therapy space.

--------------------------------------------------------------------------------

Unidentified Analyst, [4]

--------------------------------------------------------------------------------

62 total.

--------------------------------------------------------------------------------

Michael P. Rice, BioLife Solutions, Inc. - President, CEO & Director [5]

--------------------------------------------------------------------------------

62, 6-2 total with 41 in the cell and gene therapy segment.

--------------------------------------------------------------------------------

Unidentified Analyst, [6]

--------------------------------------------------------------------------------

Okay. Great. And then if you could please just shed some more color on, in your opinion, what the synergies are between the Custom Biogenic Systems freezing and cryogenic equipment and SAVSU's evo smart containers, I'd appreciate that.

--------------------------------------------------------------------------------

Michael P. Rice, BioLife Solutions, Inc. - President, CEO & Director [7]

--------------------------------------------------------------------------------

Sure, Dave. Good question. So here's how it goes. CBS' product line is for stationary freezing containers that would be at cell and gene therapy manufacturing sites, biorepositories, clinics and whatnot. The SAVSU evo line of dry vapor shippers and the other products are for transport at cryogenic temperatures and other temperatures of biologic therapies that are both time-sensitive and temperature-sensitive. So one is stationary. One is for movement across time and space.

--------------------------------------------------------------------------------

Roderick de Greef, BioLife Solutions, Inc. - CFO & Secretary [8]

--------------------------------------------------------------------------------

We believe that rather than sourcing the evo hardware from abroad, that we have the opportunity to have the products made in Detroit at CBS because fundamentally, the technology around building what is essentially a can and a can is absolutely doable at CBS.

--------------------------------------------------------------------------------

Operator [9]

--------------------------------------------------------------------------------

Our next question comes from the line of Paul Knight of Janney.

--------------------------------------------------------------------------------

Paul Richard Knight, Janney Montgomery Scott LLC, Research Division - MD, Head of Healthcare Research & Senior Equity Research Analyst [10]

--------------------------------------------------------------------------------

Mike, on the $1 million, was it 2 customers? And what was going on in each of those 2 customers if it was 2?

--------------------------------------------------------------------------------

Michael P. Rice, BioLife Solutions, Inc. - President, CEO & Director [11]

--------------------------------------------------------------------------------

Yes, Paul, correct. The softness in Q3 media was a result of 2 customers that together accounted for a nearly $1 million sequential decrease in order volume. One customer was a distributor who was transitioning into a new ERP system. Concurrently with that, Q3 is their Q1 of their fiscal year. So that's kind of a normal reload process. So those 2 dynamics were the reason there for the softness in their order volume.

The other customer, Paul, is a cell and gene therapy CMO or a contract manufacturing organization. And the CMOs, they're really at the mercy of their end customers and the clinical trial enrollment for those customers, which dictate how much product they're going to buy from any of the bioproduction tool suppliers that are supplying them critical reagents, manufacturing tools and whatnot.

--------------------------------------------------------------------------------

Paul Richard Knight, Janney Montgomery Scott LLC, Research Division - MD, Head of Healthcare Research & Senior Equity Research Analyst [12]

See the original post here:
Edited Transcript of BLFS earnings conference call or presentation 12-Nov-19 9:30pm GMT - Yahoo Finance

U.S. stem cell clinic offering unapproved therapies brings direct-to-consumer marketing to Ottawa – Ottawa Citizen

Just a few months after Health Canada began cracking down on private clinics offering unapproved stem cell therapies, at least one U.S. clinic has moved in to fill the vacuum with direct marketing to Canadian consumers.

The clinic from Burlington, Vermont, even offers shuttle buses to transport people from Ottawa to the clinic four hours away for treatment it suggests will end joint pain, among other things. Lunch and dinner are free, but each injection costs $6,880. Two for $10,880.

The treatments, using umbilical cord-derived mesenchymal stem cells, are not approved in either Canada or the United States. Health Canada warns that Canadians who travel abroad for stem cell treatments may put themselves at risk.

While stem cells, which were discovered at the University of Toronto in 1961 by James Till and Ernest McCulloch, promise to revolutionize many treatments and could offer breakthroughs for diseases, almost all are still considered experimental and have yet to be proven safe or effective. Clinical trials on numerous potential stem cell therapies are under way, including in Ottawa.

While research progresses, private stem cell clinics have popped up around the world making promises for treatments not yet proven safe or effective.

A 2018 study by Leigh Turner of the University of Minnesota Center for Bioethics found 43 clinics offering stem cell treatments in Canada and 750 in the U.S. Earlier this year, Health Canada sent Canadian clinics, including some in Ottawa, cease-and-desist letters.

Clinics in Vermont, near the Canadian border, appear to have ramped up marketing to Canadians since then. One clinic has been holding back-to-back seminars. Another says it stopped marketing in Canada after receiving a warning from Health Canada.

There have been cases of harm as a result of treatments, including two women who had permanent damage to their sight after stem cells were injected into their eyes at a Florida clinic. Other patients have been infected with unsterilized equipment and others have developed tumours at the site of stem cell injections.

A common harm, critics say, is exploitation.

Dr. Michael Rudnicki is director of the regenerative medicine program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute, says of stem cell therapy claims: If it sounds too good to be true, it probably is too good to be true.jpg

Health officials say the clinics are misusing the promise of stem cell therapy to exploit vulnerable patients.

These patients are in pain and they are suffering and they are looking for help and they are being exploited, said Dr. Michael Rudnicki, director of the regenerative medicine program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute.

If it sounds too good to be true, it probably is too good to be true.

At a recent seminar at a west-end Ottawa hotel meeting room, Roseanna Ammendolea of the Vermont Center for Regenerative Medicine told a packed room that her clinic and others like it had successfully treated people for pain related to arthritis, neuropathy and other ailments that affected joints using mesenchymal stem cells from umbilical cords. The stem cells, she claimed, are both effective and safe, saying there had been no issues with cell rejection.

We will not give injections if we feel that this injection will not be beneficial to our patients. This is why we are so successful.

Participants, including some who walked with canes and others who talked about being in pain and having mobility issues, were shown videos of people described as Canadian clients who claimed the treatments worked. One man said it was probably the best money I have spent in my life as far as my health. Another said she would do it again in a heartbeat and was able to do things she hadnt been able to do earlier.

They were also shown a slide showing long wait times for hip and knee replacements in Ontario, We are not a priority, she said. Where does that leave us? Participants werent told exactly how the stem cells were supposed to work, but claimed they had successfully improved pain and mobility issues in clients.

What the seminar goers werent told is that, even in the U.S., the treatment is not covered by health insurance because it remains unproven.

The U.S. Federal Drug Administration has issued a warning to consumers not to use cell therapies that are unapproved or unproven.

Stem cells have been called everything from cure-alls to miracle treatments. But dont believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware of potentially dangerous procedures and confirm whats really being offered before you consider anytreatment, the FDA said in a statement.

The only stem-cell-based products that are FDA-approved for use in the United States are blood-forming stem cells derived from cord blood for limited use in patients with disorders affecting the body system that is involved in the production of blood. Bone marrow is also used for these treatments, but is generally not regulated by the FDA for that use.

Health Canada has granted market authorization for a stem cell therapy to treat graft-versus-host disease and two cell-based gene therapies to treat certain cancers. Most cell therapies are still experimental.

I totally understand the skepticism of it, Doug Argento, who works at the Vermont Center for Regenerative Medicine, said in a telephone interview, but the fact is that things that are approved now and medically paid for were seen as renegade 20 or 30 years ago.

The treatment employs technology developed by Neil Riordan, founder, chairman and chief science officer of the Stem Cell Institute in Panama, using human umbilical cord tissue-derived mesenchymal stem cells. There are 41 such clinics across the U.S. Riordan also played a role in the development of a nutritional product called Stem-Kine, which producers claim without scientific backing increases the number of stem cells circulating in a persons body.

The stem cells injected in the clinic, Argento said, are from umbilical cord tissue as a result of caesarean births to reduce risk of infection.

Rudnicki, of The Ottawa Hospital Research Institute, says there is no evidence that these sorts of cells are regenerative at all. It would not pass muster in Canada.

The public has to understand that there are people out to remove them from their money.

Rudnicki says he regularly receives inquiries from people desperate to get stem cell treatments. He says he tries to connect them with clinical trials that they might be able to participate in.

Rudnicki noted there were multiple clinical trials in Canada, including treatments of autoimmune diseases, trials involving treatment for Type 1 diabetes and others.

But the use of these inappropriate cell types for treating arthritis and joints and so on is certainly not approved by Health Canada and would not be allowed in Canada under the regulations.

There is some evidence that injections of some stem cell products might have a temporary positive impact on inflammation, he said, but it will not be regenerative and will not restore function to joints. They are being sold a bill of goods.

Leigh Turner of the University of Minnesota Center for Bioethics, meanwhile, says the explosion in clinics offering unproven stem cell therapies in the U.S. is a marketplace that traffics in misrepresentation. It is easy to see how people are taken advantage of and scammed.

It is also difficult to find out about physical harms being done to patients.

There are no safety studies. We dont have good data. But we do know there have been some serious harms.

Stem cell therapies have the potential to become standard treatment in some areas, but they are not there yet, Turner said.

Businesses are tapping into genuine human suffering, desperation and also hope.

Turner also noted there was an excellent chance that the vials of liquid being injected into patients did not actually contain stem cells.

Dr. Jonathan Fenton of another stem cell clinic in Burlington, the Vermont Regenerative Medicine, said he had complained about the new clinic, the Vermont Center for Regenerative Medicine, which has a similar name and employs hard-sell tactics, he said.

His clinic takes bone marrow from patients hips and injects it. The procedure is done the same day. He says he regularly sees Canadian patients for bone marrow aspiration therapy and platelet-rich plasma treatments, using their own blood. The treatments, he says, speed healing and are allowed in the U.S. The use of bone marrow aspiration is neither proven nor allowed in Canada.

Fenton, who is secretary-treasurer of the American Academy of Orthopedic Medicine, acknowledged many people offering stem cell treatments are not doing it to the highest ethical standards.

He has filed complaints with state officials over clinics selling unsafe or fraudulent treatments. I have asked the state and federal judiciary to close down this clinic for committing fraud.

He said his platelet and bone marrow treatments were covered by a major Vermont health insurer because they saw the cost of benefits were going down and patients were requiring fewer surgeries.

He said he was told by Health Canada that he could not market in Canada. Representatives of the Vermont Center for Regenerative Medicine, meanwhile, said they had discussions with Health Canada about what they could and could not say when marketing in Canada before holding seminars in Ottawa and Halifax.

We have looked at the information provided and have not identified any immediate non-compliance with advertising regulations pertaining to Canadian health products, a Health Canada spokesperson said, adding that the agency was continuing to assess.

Back at a west-end Ottawa hotel, some participants in the seminar, including a retired pharmacist, said they were considering getting the treatments. But its expensive.

Another participant said he was skeptical. They seemed very sketchy when I went online.

epayne@postmedia.com

ALSO IN THE NEWS

Hoffman and Kaushic: Were losing the fight against superbugs

Super-agers, who live to at least 110, boast stronger immune systems, helping them fight off diseases

Spinal-cord stimulator really promising: Survivor moves legs for first time since Humboldt bus crash

More:
U.S. stem cell clinic offering unapproved therapies brings direct-to-consumer marketing to Ottawa - Ottawa Citizen

Hemophilia Treatment Market Dynamics, Pin-Point Analysis, Comprehensive Landscape, Demand Key Factors, Market Segments Regions, Therapy For Hemophilia…

(MENAFN - GetNews) Hemophilia Treatment Global Market Research Report: By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (Recombinant Coagulation Factor, Plasma-Derived Coagulation Factor, Desmopressin, Antifibrinolytic Agents), End User Global Forecast Till 2023

Hemophilia Treatment Market Overview

The global hemophilia market is forecasted to witness a steady growth of 6.10% during the forecast period between 2018 to 2023. The market valuation is slated to jump from USD 11,257.21 in 2017 to USD 16,059.17 by the end of the forecast period.

Request Free Sample Copy Available @ https://www.marketresearchfuture.com/sample_request/5688

The report published by Market Research Future (MRFR) identifies that the prevalence of hemophilia will spring up the demand for hemophilia treatment globally. The emergence of recombinant products for the treatment of hemophilia has blossomed the interest and demand for the market. The absence of a precise cure and the growing setbacks with the treatment of hemophilia has increased the need for discovering and coming up with new and effective solutions. Gene therapy is increasingly being explored and considered as a permanent solution for hemophilia and offers vast opportunities for the growth of the market.

However, the high cost associated with the treatment and the level of expenses required for consistent lab testing and imaging tests can go on to hamper the market growth of hemophilia treatment.

Hemophilia Treatment Market Segmentation

The global hemophilia treatment market segmentation is based in terms of type, end-user, and treatment.

By type, the market is categorized into hemophilia A, hemophilia B, and hemophilia C. The hemophilia A segment holds the largest share of the global market. The valuation of the segment is expected to reach USD 12.697.99 by the end of the forecast period, 2023. The calculated growth rate of the market annually has been projected to be 6.23% during the forecast period.

By treatment, the market comprises of recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, desmopressin, gene therapy, and antifibrinolytic agents. The recombinant coagulation factor concentrates is the largest market share holder with an expected CAGR of 7.01% during the review period.

By end-users, the market includes hospitals & clinics, research organization, and others. Hospitals & clinics lead this segmentation of the market and is valued at USD 7594.66 in 2017 and is expected to grow the fastest over the forthcoming years.

Hemophilia Treatment Market Regional Analysis

The regional segmentation of the hemophilia treatment market covers the following regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The Americas stand tall as the largest market share holder in the global geographical segmentation. This is due to the prevalence of the hemophilia disorder and the presence of a well-established healthcare sector. Growing expenditure in healthcare and increasing support for research and development activities are expected to aid the Americas region to maintain its leadership position. The North American market contributes more to the region than its southern counterpart.

Europe holds the second biggest market share due to a parallel growth pattern like the Americas. Moreover, government support for R & D activities for advanced medical therapies for hemophilia is another important driver to the market growth in this region.

Asia Pacific is expected to grow with the highest CAGR of 8.38% during the review period. The healthcare sector in this region is advancing at a rapid pace owing to the high disposable income in the region and expanding advanced medical facilities. The presence of a vast patient population base and a high healthcare expenditure is expected to positively impact the Asia Pacific market growth.

Hemophilia Treatment Market Competitive Landscape

The global hemophilia treatment market includes various noteworthy players like Baxter, F.Hoffmann-La Roche Ltd, Octapharma, Swedish Orphan Biovitrum AB, Pfizer Inc, CSL Behring, Sanofi, Kedrion, Novo Nordisk A/S, Bayer AG, Grifols International S.A, and Shire.

Feb 19th, 2019, Novo Nordisk announced in a press release about the US FDA approval of N8-GP, turoctocog alfa pegol, to help treat children and adults with hemophilia A in the United States. The therapy will be under the brand name of Esperoct

Feb 7th, 2019, Roche announced its joining with the World Federation of Hemophilia (WFH) Humanitarian Aid Program. The program will see the company treating more than 1,500 people with Hemophilia A across various developing countries.

Read Complete Report @ https://www.marketresearchfuture.com/reports/hemophilia-treatment-market-5688

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact Company Name: Market Research Future Contact Person: Abhishek Sawant Email: Send Email Phone: +1 646 845 9312 Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar City: Pune State: Maharashtra Country: India Website: https://www.marketresearchfuture.com/reports/hemophilia-treatment-market-5688

MENAFN1811201900703268ID1099290278

Read this article:
Hemophilia Treatment Market Dynamics, Pin-Point Analysis, Comprehensive Landscape, Demand Key Factors, Market Segments Regions, Therapy For Hemophilia...

Global Regenerative Therapies for Osteoarthritis Market Insights 2019 : Acelity, Mesoblast, Nuo Therapeutics, Astellas Pharma – Breakaway Trends

The global "Regenerative Therapies for Osteoarthritis Market" report offers the analyzed data of the Regenerative Therapies for Osteoarthritis market in categorized view. The Regenerative Therapies for Osteoarthritis market offers a common platform with multiple opportunities to many firms, associations, industries, and other products and services providers Acelity, Mesoblast, Nuo Therapeutics, Astellas Pharma, Organovo, Orgenesis, Sanofi, Athersys, Shire, Cytori Therapeutics to compete among themselves by offering better products and acceptable services to the clients and expand significantly at the global level. The global Regenerative Therapies for Osteoarthritis market report offers summarized detail about the major market holding key contenders alongside the recent developing industries in the market relating to the revenue, demands, sales, and product quality.

Apply here for the sample copy of the report @: https://www.reportsbuzz.com/request-for-sample.html?repid=78717

Furthermore, The report presents a detailed segmentation Cell Therapy, Tissue Engineering, Gene Therapy, Market Trend by Application Hospitals, Ambulatory Surgical Centers, Orthopaedic Clinics, Research Institutes of the global market based on technology, product type, application, and various processes and systems. The report contains information on a large number of highly reputed organizations, vendors, and manufacturers in the global Regenerative Therapies for Osteoarthritis market.

The current status and future outlook of the market growth is also included in the Regenerative Therapies for Osteoarthritis market report. The report is created after deep research and thorough investigation of the gathered data in different divisions of the market that needs technological ideas, theoretical analysis, and its relevancy. The report includes the various key factors that can considerably accelerate and slow down the growth rate of the market. The report provides information about the future development of the industry, based on its past data along with the current evaluated data about the Regenerative Therapies for Osteoarthritis market region-wise.

Read Detailed Index of full Research Study at:: https://www.reportsbuzz.com/78717/global-regenerative-therapies-for-osteoarthritis-market-outlook-2018/

To provide the clarified representation of the current and upcoming growth trends of the market, the report provides the execution and attributes of the Regenerative Therapies for Osteoarthritis market that are analyzed on the basis of the qualitative and quantitative process. Through the report, one can be able to take quick and precise business decisions by getting familiar with every aspect of the market. The Regenerative Therapies for Osteoarthritis market report represents the analyzed data through graphs, charts, and figures for less complexity and better understandability about the Regenerative Therapies for Osteoarthritis market.

There are 15 Chapters to display the Global Regenerative Therapies for Osteoarthritis market

Chapter 1, Definition, Specifications and Classification of Regenerative Therapies for Osteoarthritis, Applications of Regenerative Therapies for Osteoarthritis, Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Regenerative Therapies for Osteoarthritis, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Regenerative Therapies for Osteoarthritis Segment Market Analysis (by Type);Chapter 7 and 8, The Regenerative Therapies for Osteoarthritis Segment Market Analysis (by Application) Major Manufacturers Analysis of Regenerative Therapies for Osteoarthritis ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Cell Therapy, Tissue Engineering, Gene Therapy, Market Trend by Application Hospitals, Ambulatory Surgical Centers, Orthopaedic Clinics, Research Institutes;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Regenerative Therapies for Osteoarthritis ;Chapter 12, Regenerative Therapies for Osteoarthritis Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Regenerative Therapies for Osteoarthritis sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: https://www.reportsbuzz.com/inquiry-for-buying.html?repid=78717

Reasons for Buying Regenerative Therapies for Osteoarthritis market

This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Sorry! The Author has not filled his profile.

Read the original:
Global Regenerative Therapies for Osteoarthritis Market Insights 2019 : Acelity, Mesoblast, Nuo Therapeutics, Astellas Pharma - Breakaway Trends

Abuse in cell banking services a global problem – Bioprocess Insider – BioProcess Insider

The International Society for Cell and Gene Therapy (ISCT) has formed a consortium to tackle what it says is a rising number of unscrupulous and unproven cell banking players.

With the rise of interest in the cell and gene therapy sector, industry and the market have been plagued with unproven products and services from rogue actors looking to profit from ill-informed and sometimes desperate patients.

The US Food and Drug Administration (FDA) laid down a framework to tackle unapproved stem cell clinics, for example, and has issued warning letters,seized productsand instigated legal action to crack down on unscrupulous actors who often co-opt scientific terms and offer tokens of scientific legitimacy without backing from scientific studies and clinical evidence.

Image: iStock/Vitezslav Vylicil

Beyond stem cell clinics deceiving patients, with the approval of more cell and gene therapies, we see these profiteers moving to cell banking marketed to healthy people as well as patients, Laertis Ikonomou, co-chair off the International Society for Cell and Gene Therapy Presidential Task Force (PTF) on the Use of Unproven Cellular Therapies, told Bioprocess Insider.

There is potential for abuse in that the banking services may refer to direct-to-consumer unproven and unethical cell-based interventions will use cells from such cell banks. With global marketing and point of service kits, this is a borderless problem for all.

As such, the ISCT has formed a global consortium of professional and education societies to help combat the rise in the number of unproven commercial cell banking services. The consortium includes: The International Society for Stem Cell Research (ISSCR), Society for Immunotherapy of Cancer (SITC), American Society for Transplantation and Cellular Therapy (ASTCT), American Society of Gene & Cell Therapy (ASGCT), European Society for Blood and Marrow Transplantation (EBMT), Foundation for the Accreditation of Cellular Therapy (FACT), Joint Accreditation Committee ISCT-EBMT (JACIE) and the Forum for Innovative Regenerative Medicine (FIRM).

We do not currently have detailed statistics specifically on the number of cell banking services per region. It appears most are concentrated in the US, United Kingdom, and India, said Laertis Ikonomou.

Nevertheless, we consider such services to be part of a global market for unproven cellular therapies. This market has been estimated to be worth as much as $2.4 billion (2.13 billion). It is also estimated that currently approximately 60,000 patients every year globally are treated with unproven cellular therapies and charges for individual treatments can be as much as $40,000 (35,500) per treatment.

The initiative looks to protect legitimate cell-based product development and patients in various ways, Ikonomou said.

Any questionable offer of unproven cell-based products and services hurts the field of regenerative medicine. It erodes the publics trust and it gives the false impression that it is acceptable to offer products that have not been proven safe and effective.

Our collaborative effort aims to highlight these issues. We also want to demonstrate to patients the gap between the real clinical potential of such a service which is unclear at the moment and the overblown advertising claims of businesses offering commercial cell banking services.

While industry-led efforts such as this are necessary, he added increased regulatory enforcement such as the FDAs recent injunctions against unproven tissue-based clinics can rein in businesses that offer questionable cell-related services or products.

Exaggerated and misleading claims of future clinical use for banked cells may also fall under the purview of the US Federal Trade Commission. ISCT is in ongoing communication with regulatory and professional societies around the world, through the ISCT led Cell Therapy Liaison Meetings with FDA, Health Canada, and additional channels.

See more here:
Abuse in cell banking services a global problem - Bioprocess Insider - BioProcess Insider

Anti-Aging Products and Therapies Market Outlook: Investors Still Miss the Big Assessment – The Market Journal

Advance Market Analytics released a comprehensive study of 200+ pages on Anti-Aging Products and Therapies market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are Allergan plc (Ireland), Ipsen (France), Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (China), Estee Lauder Companies Inc. (United States), Avon Products, Inc. (United Kingdom), Galderma S.A. (Switzerland), LG Life Sciences, Ltd. (South Korea), Bohus Biotech AB (Sweden), Imeik Technology Development Co Ltd (China), Merck & Co., Inc. (United States), Gaoxin Zhangtong Co. Ltd. (China)

Request a sample report @ https://www.advancemarketanalytics.com/sample-report/36862-global-anti-aging-products-and-therapies-market

Due to rise in aging populations in several developed and developing countries, the anti-aging products and therapies market will grow robustly over the forecasted period. In addition to this, the rising number of medical tourism for cosmetic procedures, as well as technological advancement in the field of anti-aging will further escalate the demand for anti-aging treatments and ultimately anti-aging products. Moreover, the growing adoption of minimally invasive anti-aging treatments and introduction to non-invasive laser treatments will attract global population. However, some of the severe side effects for the skin treatments might stagnate the demand for anti-aging products and treatments. Aging relates to maturing or growing old in terms of endurance, agility, strength, basal metabolism, speed of reaction, hearing acuity and many others. In case of geriatric population, the skin drier & less elastic; bones are comparatively brittle, and the teeth are shed.

Market Segmentationby Type (Human Growth Hormone, Stem Cell, Placenta, Botulinum Toxin, Hyaluronic Acid), Application (Anti-Pigmentation Therapy, Anti-Cellulite Treatment, Anti-Wrinkle Treatment, Acne Management, Scar Treatment, Others), Active Ingredients (Retinol, Peptides, Argirelline), Distribution Channel (Dermatology Clinics, Hospitals, Pharmacies, Drug Stores, Rejuvenation Centers, Others.), Service (BOTOX, Proteomics, Gene Therapy, HRT, Dermal Fillers, Plastic Surgery)

Make an enquiry before buying this Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/36862-global-anti-aging-products-and-therapies-market

Whats Trending in Market: Introduction to Highly Advanced Skin Treatments such as Neuromodulators For Tauter Skin

Adoption of New Age Fillers like Hyaluronic acid and Calcium Hydroxyapatite Fillers

Growth Drivers: Increasing Geriatric Population across the Globe will boost the Demand

Rising Health Consciousness Among Consumers

Restraints: Significant Side-Effects of the Dermal Treatments for instance; Chemicals Available in Cosmetic Products are Found in Biopsies from Breast Tumors

Excessive Use might Disturb the Hormone Function of Consumer

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/36862-global-anti-aging-products-and-therapies-market

Country level Break-up includes:North America (United States, Canada and Mexico)Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

On Special Request we do offer a dedicated and focus report on regional or by country level scope.

GET FULL COPY OF United States Anti-Aging Products and Therapies market study @ USD 2000

And, Asia-Pacific Anti-Aging Products and Therapies market study @ USD 2500

Major Highlights of TOC:

Chapter One: Market Overview

Scope/Objective of the Study

Chapter Two: Executive Summary - Free of Cost

Chapter Three: Market Dynamics USD400

Market Drivers, Market Challenges, Market Trends

Chapter Four: Market Factor Analysis USD400

Supply/Value Chain Analysis, Porters Five Forces, PESTEL analysis, Market Entropy, Patent & Trademark Analysis, Market Development Scenario

Chapter Five and Seven: Global Anti-Aging Products and Therapies, by Market Segmentation and Region (value, volume**) (2013-2024) USD2400

Global Anti-Aging Products and Therapies

By Type (Human Growth Hormone, Stem Cell, Placenta, Botulinum Toxin, Hyaluronic Acid)

By Application (Anti-Pigmentation Therapy, Anti-Cellulite Treatment, Anti-Wrinkle Treatment, Acne Management, Scar Treatment, Others)

By Active Ingredients (Retinol, Peptides, Argirelline)

By Distribution Channel (Dermatology Clinics, Hospitals, Pharmacies, Drug Stores, Rejuvenation Centers, Others.)

By Service (BOTOX, Proteomics, Gene Therapy, HRT, Dermal Fillers, Plastic Surgery)

Global Anti-Aging Products and Therapies Region

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Chapter Six: Global Anti-Aging Products and Therapies Manufacturers/Players Analysis USD1200

Competitive Landscape (Direct & Indirect Competitors), Market Share Analysis, Peer Group Analysis (2018), BCG Matrix, Company Profile, Downstream Buyers & Upstream Suppliers

..

Chapter Nine: Methodology/Research Approach, Data Source, Disclaimer

** If applicable* Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=36862

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:CRAIG FRANCIS (PR & Marketing Manager)sales@advancemarketanalytics.comPh: +1 (206) 317 1218

View original post here:
Anti-Aging Products and Therapies Market Outlook: Investors Still Miss the Big Assessment - The Market Journal

Tip Sheet: A clever way to make an AIDS vaccine; how a common cancer mutation actually drives cancer; and a new process that regulates red blood cell…

MEDIA CONTACT

Available for logged-in reporters only

Cancer and infectious disease

Newswise New trial aims to curb HPV-related cancers in HIV+ women and children Fred Hutch researchers just received funding from the National Institutes of Health for a five-year collaboration designed to help a population at high risk for cervical and other HPV-related cancers: women and children living with HIV. Through the project, which comes with around $1.8 million each year, researchers will conduct three separate trials in three major Latin American cities: Lima, Peru; Rio de Janeiro, Brazil; and Santa Domingo, Dominican Republic. Many cancers have been linked to the human papillomavirus, or HPV, including cervical, anal, penile, vulvar and some head and neck cancers. While cervical cancer rates in the U.S. have stayed low for years thanks to screening and an effective HPV vaccine, it remains the fourth-leading cause of cancer and cancer death worldwide.Media contact: Claire Hudson, crhudson@fredhutch.org, 206.667.7665

_____________________________________________________________________________________________________________________HIV/AIDS research

Baiting for B cells: A clever new way to make an AIDS vaccine Researchers at Fred Hutch have developed a new strategy to counter the frustrating ability of HIV to sidestep vaccines designed to block it. In a pair of papers recently published in the Journal of Experimental Medicine, Hutch vaccine researchers explain how they were able to use a tiny chunk of protein as bait to fish for extremely rare white blood cells hidden within ordinary blood. When these rare B cells bind with the bait, they multiply and are not so rare anymore. Thats important, because these B cells are just a few evolutionary steps away from generating with some nudging from a series of additional injections the kind of long-lasting immune responses needed for an effective HIV vaccine. Media contact: Claire Hudson, crhudson@fredhutch.org, 206.667.7665

_____________________________________________________________________________________________________________________Healthcare Economics

Fred Hutch issues report on cancer care in Washington state The Community Cancer Care in Washington State: Quality and Cost Report 2019 measured performance in four areas among 29 clinics by linking health utilization data with cost data from public and private insurers in the state. The report found room for improvement in reducing emergency department visits and hospitalizations during chemotherapy and in providing appropriate end-of-life care. The report is part of a six-year collaboration among patient partners, hospitals and clinics delivering cancer care, health insurance plan administrators, researchers, health quality organizations, policymakers and government leaders led by the Hutchinson Institute for Cancer Outcomes Research, a research group at Fred Hutch whose mission is to improve cancer care in ways that will reduce the economic and human burden of cancer. Media contact: Claire Hudson, crhudson@fredhutch.org, 206.667.7665

_____________________________________________________________________________________________________________________Public Health Sciences

How a common cancer mutation actually drives cancer and how to correct it A new, multicenter study led by researchers at Fred Hutch and Memorial Sloan Kettering Cancer Center determined how a single mutation in splicing factor 3b subunit 1(SF3B1), the most frequently mutated splicing factor gene, drives the formation of many cancers. The findings were published earlier this month in the journal Nature. Dr. Robert Bradley, associate member of Fred Hutchs Public Health Sciences and Basic Sciences divisions, andDr. Omar Abdel-Wahab, associate member of Memorial Sloan Ketterings Human Oncology and Pathogenesis Program, led the study to discover howSF3B1gene mutations cause cancer.Media contact: Tom Kim, tomkim@fredhutch.org, 206.667.6240 _____________________________________________________________________________________________________________________Human Biology

Scientists discover new process shaping red blood cell development Fred Hutch scientists have discovered a process that regulates the earliest stages of red blood cell development. The findings, published recently in the journal Nature Communications, could shed light on what goes wrong in certain blood cancers and anemias. The team showed for the first time that developing red blood cells use a particular molecular process to ensure that red blood cell-specific proteins are made. Blocking the molecular machinery prevented the normal development of blood cells. Media contact: Molly McElroy, mwmcelro@fredhutch.org, 206.667.6651

Age-old arms race points way to new-and-improved antiviral proteinFred Hutch scientists have recently shown that they could use insights from the ancient tug-of-war between viruses and their hosts to evolve a better antiviral protein in the lab. The work was published last month in the journal PLOS Biology.The findings address fundamental questions about evolution, including whether antiviral genes that adapt against certain viruses become less equipped to deal with new viral challenges. Media contact: Molly McElroy, mwmcelro@fredhutch.org, 206.667.6651

_____________________________________________________________________________________________________________________October Recognitions

Researchers at Fred Hutch are often recognized for their work. Were proud to celebrate their achievements and grateful to the awarding organizations.

Infectious Diseases Society to honor Dr. Michael Boeckh

Fred Hutchled team receives $6M to study deadly brain tumor

New study aims to transform myeloma therapy into cure

Dr. M. Elizabeth Betz Halloran elected to National Academy of Medicine

# # #

AtFred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutchs pioneering work inbone marrow transplantationled to the development ofimmunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nations first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Womens Health Initiative and the international headquarters of theHIV Vaccine Trials Network.

Original post:
Tip Sheet: A clever way to make an AIDS vaccine; how a common cancer mutation actually drives cancer; and a new process that regulates red blood cell...

Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) – The Market Expedition

obal Cell Therapy Technologies Marketwas valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

Do Inquiry Before Purchasing Report Here:https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at:https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Original post:
Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) - The Market Expedition

Davenport & Company Upped By $3.56 Million Its Sgmo (SGMO) Holding; EMPOWER CLINICS ORDINARY SHARES (EPWCF) Shorts Raised By 2360% – MS Wkly

Davenport & Company Llc increased Sgmo (SGMO) stake by 516.32% reported in 2019Q2 SEC filing. Davenport & Company Llc acquired 355,876 shares as Sgmo (SGMO)s stock rose 5.54%. The Davenport & Company Llc holds 424,801 shares with $4.58M value, up from 68,925 last quarter. Sgmo now has $1.05 billion valuation. The stock increased 3.16% or $0.29 during the last trading session, reaching $9.46. About 761,245 shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has declined 8.32% since November 6, 2018 and is downtrending. It has underperformed by 8.32% the S&P500. Some Historical SGMO News: 16/05/2018 Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease; 23/05/2018 Biotech Analysis Central Preview Series: Sangamo Therapeutics; 25/04/2018 SANGAMO THERAPEUTICS OFFERING PRICES AT $16.25/SHR; 17/04/2018 SANGAMO THERAPEUTICS SAYS EXECS EMAIL WAS COMPROMISED; 17/04/2018 SANGAMO THERAPEUTICS: CONFIDENTIAL, SENSITIVE INFO ACCESSED; 17/04/2018 SANGAMO THERAPEUTICS-PROPRIETARY, CONFIDENTIAL, OTHER SENSITIVE INFORMATION OF CO, OTHER ENTITIES ACCESSED, MAY HAVE BEEN COMPROMISED DUE TO INCIDENT; 17/04/2018 SANGAMO THERAPEUTICS INC DATA SECURITY INCIDENT WAS LIMITED TO COMPROMISE OF SENIOR EXECUTIVES COMPANY EMAIL ACCOUNT FOR APPROXIMATELY 11 WEEKS; 23/04/2018 DJ Sangamo Therapeutics Inc, Inst Holders, 1Q 2018 (SGMO); 03/05/2018 Sangamo Therapeutics: Michael Holmes Promoted to Chief Technology Officer; 01/05/2018 Sangamo Therapeutics Announces Presentations At 2018 Annual Meeting Of The American Society Of Gene & Cell Therapy

EMPOWER CLINICS INC ORDINARY SHARES (OTCMKTS:EPWCF) had an increase of 2360% in short interest. EPWCFs SI was 12,300 shares in November as released by FINRA. Its up 2360% from 500 shares previously. With 22,200 avg volume, 1 days are for EMPOWER CLINICS INC ORDINARY SHARES (OTCMKTS:EPWCF)s short sellers to cover EPWCFs short positions. It closed at $0.029 lastly. It is down 0.00% since November 6, 2018 and is . It has by 0.00% the S&P500.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Finance.Yahoo.com which released: Is Sangamo Therapeutics, Inc. (SGMO) Going to Burn These Hedge Funds? Yahoo Finance on October 28, 2019, also Fool.com with their article: Should Investors Buy or Sell Sangamo Therapeutics Right Now? Motley Fool published on October 08, 2019, Businesswire.com published: Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer Business Wire on November 01, 2019. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Finance.Yahoo.com and their article: What Kind Of Shareholder Owns Most Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Stock? Yahoo Finance published on October 01, 2019 as well as Finance.Yahoo.coms news article titled: If You Had Bought Sangamo Therapeutics (NASDAQ:SGMO) Stock Three Years Ago, You Could Pocket A 93% Gain Today Yahoo Finance with publication date: May 05, 2019.

Investors sentiment increased to 1.57 in Q2 2019. Its up 0.29, from 1.28 in 2019Q1. It is positive, as 24 investors sold SGMO shares while 32 reduced holdings. 26 funds opened positions while 62 raised stakes. 73.13 million shares or 14.12% more from 64.08 million shares in 2019Q1 were reported. Advisory Svcs Ntwk Ltd accumulated 6,267 shares or 0% of the stock. Prelude Management Ltd Liability Corp has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Cranbrook Wealth Mgmt Llc stated it has 1,620 shares or 0% of all its holdings. Baker Bros Lp stated it has 999,823 shares. Geode Mgmt Limited Liability reported 1.49 million shares stake. California State Teachers Retirement Systems has 176,863 shares for 0% of their portfolio. Rafferty Asset Limited Liability Com reported 262,377 shares. Vigilant Cap Mngmt Limited invested in 5,000 shares or 0.01% of the stock. Principal Financial holds 0% or 28,192 shares. Baldwin Brothers Incorporated Ma reported 1,500 shares. Cubist Systematic Strategies Ltd Liability Co reported 68,478 shares. Nuveen Asset Mgmt Lc, a Illinois-based fund reported 790,682 shares. Goldman Sachs Grp Inc Inc invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Tiverton Asset Mngmt Ltd Company holds 0% or 7,316 shares. Legal & General Gp Public Limited Com accumulated 23,425 shares or 0% of the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the original:
Davenport & Company Upped By $3.56 Million Its Sgmo (SGMO) Holding; EMPOWER CLINICS ORDINARY SHARES (EPWCF) Shorts Raised By 2360% - MS Wkly

Dr Batra’s have launched a new genetics-based therapy that predicts future diseases – Gulf Today

Dr Mukesh Batra, the owner of Dr Batras clinics.

Mitchelle DSouza, Sub-editor/Reporter

The founder and chairman of Dr Batras group of companies, Dr Mukesh Batras name has become a byword for homeopathy.

The pioneering Indian doctor-cum-entrepreneur has built a legacy which includes a network of clinics, day-care aesthetic centres, and health and wellness products.

We caught up with Dr Batra at his Healthcare City clinic in Dubai, where he spoke at length about the workings of homeopathy and introduced us to the new Geno-Homeopathy treatment launched by the brand.

Can you explain what homeopathy treatment is for those who dont have a clear understanding? How does it work in comparison to conventional medicine?

Theres actually a misconception that its not well known. For emergencies and conventional problems, allopathy is the go-to. Like a heart attack, surgeries, gunshot wounds and so on.

However, homeopathy is safe for anything that is chronic and long lasting such as psychosomatic problems like stress, anxiety, and depression related issues; allergies, skin and hair problems.

We treat a wide range of illnesses such as asthma, arthritis, anxiety, depression, backache, cervical spondylitis, kidney stones in primary stage, warts, piles, PCOD, nasal polyps etc.

It has no side-effects and is completely painless and non-invasive. It goes to the root of the problem, nipping it in the bud, rather than just supressing it temporarily with pain killers.

"People are getting disillusioned with chemical medication, its side effects and opting for substances that are natural and safe, and holistic remedies, which homeopathy includes.

Is it true that homeopathy is slower in addressing an ailment in comparison to allopathy?

Its partly true, but not entirely. If you come to allopathy for a chronic sinus problem, you pop a pill and supress it. Similarly for a skin allergy, an ointment will supress the symptoms. The moment you stop, it flares up again.

So when you look at suppression, it is quick in allopathy, but thats not a cure. In conventional medicine, treatment is as slow as homeopathy or maybe even slower

For instance, a patient may be supressing his/her migraine or skin problem for the last 10 years with allopathy by taking pain killers and anti-inflammatories but without a proper solution.

However, if he/she were to take homeopathy for just 10 months, it would cure it, and hence that makes it much faster and effective as it gets to the root of the cause.

The reason it may feel seemingly long is because most illnesses are chronic, long-standing and deep-rooted.

Geno-Homeopathy treatment employs a gene test to predict, pre-empt and treat an illness. Charles Bertram/TNS

Can you give us an insight into the new Geno-Homeopathy treatment launched in the UAE?

As you may be aware, genetic DNA studies have been around for some years and have become more popular off late, thanks to Angelina Jolie creating awareness by positively testing herself for a cancer gene.

This helps predict and pre-empt an illness. How this works is that you have genes that are inherited, with 99.9 per cent of them being normal. But 0.1 per cent genes can be faulty and that percentage decides what diseases we carry.

A gene is like a finger print, it never changes. So just like you would use your finger print or pupil for identity, this is used for gene mapping through a simple sputum test. Now that 0.1 percentage gene decides how healthy I can be and which diseases I am likely to suffer from.

So with Geno-Homeopathy we can now analyse those 0.1 per cent genes. We completed one year in India in September and did 15,000 cases of genetic mapping.

This technique gives you your disease propensity and can tell you, for example, whether youll go bald five or 10 years from now; if youre prone to heart attack or diabetes it will tell you when youre likely to get it.

Post an analysis, a homeopathic treatment is offered to the patient to treat a condition. So this can be almost life-saving and is now within peoples reach in the UAE.

Angelina Jolie found out through genetic testing similar to Geno-Homeopathy that she is at a high risk of developing breast cancer.Marechal Aurore/TNS

There are a lot of cynics out there who question the scientific basis of homeopathy. What do you have to say to that?

A research we conducted three to four years ago found that a majority of people in Indian metros were taking homeopathy as the first choice of treatment. Pharma is growing at 10 per cent while homeopathy is growing at 30 per cent all over the world.

People are getting disillusioned with chemical medication, its side effects and opting for substances that are natural and safe, and holistic remedies, which homeopathy includes.

To give you a little perspective, there are around 300 people dying of drug reaction in America alone everyday which is equal to a Boeing crash. But it doesnt get as much attention, which can be pinned on the strong medical lobby.

So theres a gradual shift happening from allopathy to homeopathy not just in India but all over the world.

That being said, there are a lot of cynics and the lobbies that plant various stories. In spite of all this homeopathy is growing exponentially. The proof of the pudding is in eating it, so people should give it a try before denouncing it.

See the article here:
Dr Batra's have launched a new genetics-based therapy that predicts future diseases - Gulf Today